Competitive landscape

View All

Delveinsight
LAG-3 Antagonists, TIM-3 Antagonists; OX40 Agonists- Pipeline Insights, 2016 – A DelveInsight Report

DelveInsight, the leading market research and consulting company has added new report “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2016” to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise pro...

Find More

Delveinsight
Chimeric Antigen Receptor T cell Immunotherapy Market Analysis and Forecast

DelveInsight, the leading market research and consulting company has added new report    “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016”to its portfolio. Reports Highlights: ·      CAR-T cell Therapy Pipeline scenario ·      Collaborations &...

Find More

Delveinsight
Zemplar Drug Insights, 2016

DelveInsight, the leading market research and consulting company has added new report Zemplar -Drug Insights, 2016 to its portfolio. With this launch DelveInsight now has 400+ Reports on Drug Insight. In addition to this our research expertise provides our clients with up to date information of market till date orde...

Find More

Delveinsight
Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016

DelveInsight, the leading market research and consulting company has added new report  Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clien...

Find More

Delveinsight
Peripheral Lung Cancer Pipeline Insights, 2016

DelveInsight, the leading market research and consulting company has added new report Peripheral Lung Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date inf...

Find More

Delveinsight
DelveInsight’s Market Research Reports

DelveInsight has established its strong presence in therapeutic areas and has launched Analytical Reports on indication, mechanism of actions, drugs, Global API Manufacturers and specialized Reports on Gene Therapy, Anticoagulants, PD-1 and PDL-1, CART and Antibody Drug conjugates. After tremendous success last yea...

Find More

Delveinsight
Small interfering RNA (siRNA) Therapeutics

In the years since the discovery of RNA interference, researchers have found that this process is far more widespread than we might expect, and that small pieces of RNA play many functional roles. Small (or short) interfering RNA (siRNA) is the most commonly used RNA interference (RNAi) tool for inducing short-term ...

Find More

Delveinsight
Orphan drug development strategies

Introduction A disease that has not been adopted by the pharmaceutical industry because it provides little financial incentive for the private sector to make and market new medications to treat or prevent it.  An orphan disease may be a rare disease or a common disease that has been ignored because it is far more pr...

Find More

Delveinsight
Oral Mucositis Pipeline Insights, 2015- A DelveInsight Report

In current scenario chemotherapies and radiations are prominently used to cure cancer which results in adverse effects. Oral Mucositis is one such adverse effect that results in ulceration in the mouth due to high dosage of chemotherapy. The patients undergoing head and neck cancer chemotherapy are at a high risk of...

Find More

Delveinsight
Outbreak of Companies Challenging New Pathways for Treatment of Pulmonary Arterial Hypertension

Drugs with better pharmacodymics and improved treatment algorithm with antiproliferative and anti-inflammatory treatments are needed! Pulmonary arterial hypertension (PAH) is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction and vascular remodeling that i...

Find More